Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 6Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Sarcoma 1

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 17Ovarian Neoplasms 14Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Glioblastoma 7Liver Neoplasms 6Lung Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Brain Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Melanoma 3Carcinoma, Ovarian Epithelial 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Colorectal Cancer Metastatic 2Brenner Tumor 2Advanced Solid Tumors 2Adenocarcinoma, Mucinous 2Virus Diseases 1

Interventions

pembrolizumab 2Pemetrexed 2Docetaxel 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1trametinib 1spartalizumab 1sotorasib 1sintilimab 1palbociclib 1netrin-1 inhibitor NP137 1atezolizumab 1Panitumumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Injections 1Fluorouracil 1Everolimus 1Drug Therapy 1Cetuximab 1Afatinib 1ASP1570 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Solid Tumors × Bevacizumab × Clear all
NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Active not recruiting
226 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡